Sarah Sharman Moser

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 6

Top Topics

Smoking Cessation

Quality Improvement

Cross Sectional

Top Venues

Journal of pharmaceutical policy and practice

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Sarah Sharman Moser, Frank Tanser, Nava Siegelmann-Danieli, Lior Apter, Gabriel Chodick, Josie Solomon
The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer. Journal of pharmaceutical policy and practice 16 (1) (2023)
Sarah Sharman Moser, Frank Tanser, Nava Siegelmann-Danieli, Lior Apter, Gabriel Chodick, Josie Solomon
The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer. Journal of pharmaceutical policy and practice 16 (1) (2023)
Sarah Sharman Moser, Orr Friedman Mazursky, Hadas Shalev, Lior Apter, Gabriel Chodick, Nava Siegelmann-Danieli
Real-world outcomes of patients with metastatic endocrine-responsive breast cancer receiving palbociclib-based combinations. Future oncology (London, England) (2023)
Sarah Sharman Moser, Frank Tanser, Nava Siegelmann-Danieli, Lior Apter, Gabriel Chodick, Josie Solomon
The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer. Journal of pharmaceutical policy and practice 16 (1) (2023)
Sarah Sharman Moser, Frank Tanser, Nava Siegelmann-Danieli, Lior Apter, Gabriel Chodick, Josie Solomon
The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer. Journal of pharmaceutical policy and practice 16 (1) (2023)
Sarah Sharman Moser, Lior Apter, Ashwini Arunachalam, Thomas Burke, Varda Shalev, Gabriel Chodick, Nava Siegelmann-Danieli
Real-world study of PD-L1 testing patterns and treatment distribution in patients with metastatic non-small-cell lung cancer in Israel. Immunotherapy 13 (10) (2021)